Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2020 Filed Jun 2, 2020 21:01 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 12,814 | $62.00 | $794,468.00 |
DisclosureSEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 1 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 23 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2020. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:01 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,000 | Not disclosed Strike: $63.95 | Not disclosed |
DisclosureSEC source: 0001567619-20-010833 · doc1.xml · derivative · entry 3 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,422 Underlying: Common Stock · 4,000 shares Expires 2025-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:01 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 4,000 | $295.61 | $1,182,432.80 |
DisclosureSEC source: 0001567619-20-010833 · doc1.xml · nonDerivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $295.68 to a high of $295.735 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:01 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 4,000 | $63.95 | $255,800.00 |
DisclosureSEC source: 0001567619-20-010833 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 10,000 | $294.99 | $2,949,900.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 10,000 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC |
Turner Kathy VCorporate Vice President
|
SaleCommon Stock | 2,690 | $301.00 | $809,690.00 |
DisclosureSEC source: 0001567619-20-010835 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,112 F1 · balance_after: Includes 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 23,000 | $297.29 | $6,837,670.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 20,000 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 5,000 | $297.18 | $1,485,900.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 43,000 Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 7,422 | Not disclosed Strike: $63.95 | Not disclosed |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · derivative · entry 6 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 7,422 shares Expires 2025-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not spplicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,974 | Not disclosed Strike: $64.69 | Not disclosed |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · derivative · entry 5 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,974 shares Expires 2024-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not spplicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 7,422 | $286.66 | $2,127,565.29 |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · nonDerivative · entry 4 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,696 Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionCommon Stock | 7,422 | $63.95 | $474,636.90 |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · nonDerivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 5,974 | $286.66 | $1,712,486.53 |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · nonDerivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,696 Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:03 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionCommon Stock | 5,974 | $64.69 | $386,458.06 |
DisclosureSEC source: 0001567619-20-010595 · doc1.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:02 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 30,000 | $293.41 | $8,802,300.00 |
DisclosureSEC source: 0001567619-20-009830 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 48,000 Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,028 | Not disclosed Strike: $64.24 | Not disclosed |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,028 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F7 · derivative.exercise_date: Grant of option to buy 10,071 shares of Issuer common stock that became exercisable in five annual installments beginning June 1, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 11,110 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,110 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 5,555 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2016 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,126 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · derivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,126 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 6,039 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
SaleCommon Stock | 4,028 | $299.29 | $1,205,558.65 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,772 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $299.25 to a high of $299.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionCommon Stock | 4,028 | $64.24 | $258,758.72 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
SaleCommon Stock | 11,110 | $298.75 | $3,319,088.06 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,772 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $298.324 to a high of $299.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionCommon Stock | 11,110 | $79.54 | $883,689.40 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
SaleCommon Stock | 1,126 | $298.28 | $335,868.68 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,772 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $298.27 to a high of $298.323 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:15 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionCommon Stock | 1,126 | $62.00 | $69,812.00 |
DisclosureSEC source: 0001567619-20-009603 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020. Read SEC document |
| May 11, 2020 Filed May 13, 2020 21:02 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 20,000 | $297.80 | $5,956,000.00 |
DisclosureSEC source: 0001567619-20-009830 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 78,000 Read SEC document |
| May 11, 2020 Filed Aug 28, 2020 21:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,467 Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 21,130 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,940 Underlying: Common Stock · 21,130 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 2,601 | $293.40 | $763,124.56 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $293.13 to a high of 294.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 3,440 | $292.44 | $1,005,993.26 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,068 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $292.07 to a high of $293.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 9,953 | $291.41 | $2,900,450.51 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,508 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 5,136 | $290.59 | $1,492,490.27 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,461 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionCommon Stock | 21,130 | $62.00 | $1,310,060.00 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 8, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 11,000 | $292.25 | $3,214,750.00 |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 98,000 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
Vandebroek Sophie V.Director
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009380 · doc1.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
Vandebroek Sophie V.Director
|
GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009380 · doc1.xml · derivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,741 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · derivative · entry 7 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · derivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515 Underlying: Common Stock · 370 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F5 · price: Not applicable. F3 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2020 Szostak IDEXX GRAT Disclosed balance after: 10,217 F2 · ownership.nature: The reporting person is the settlor and trustee of the 2020 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 0 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 7,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 10,217 F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 584 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 6,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 Szostak IDEXX GRAT Disclosed balance after: 0 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
SAMAD SAMDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009378 · doc1.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
SAMAD SAMDirector
|
GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009378 · doc1.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
Kingsley Lawrence DDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 487 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 4 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487 Underlying: Common Stock · 487 shares Expires 2030-05-05 F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Chairman of the Board. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
Kingsley Lawrence DDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 3 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
Kingsley Lawrence DDirector
|
GrantDeferred Stock Unit · Derivative | 141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 2 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,740 Underlying: Common Stock · 141 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Chairman of the Board. F4 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC |
Kingsley Lawrence DDirector
|
GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,599 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F4 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:02 UTC |
JUNIUS DANIEL MDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009376 · doc1.xml · derivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:02 UTC |
JUNIUS DANIEL MDirector
|
GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009376 · doc1.xml · derivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,163 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.